ESC Premium Access

Positioning of the topic - First-line therapies in heart failure with reduced ejection fraction (HFrEF)

Congress Presentation

About the speaker

Professor Gerasimos Filippatos

National & Kapodistrian University of Athens, Athens (Greece)
55 presentations
4 followers

7 more presentations in this session

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - PRO

Speaker: Doctor M. Packer (Dallas, US)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - CON

Speaker: Professor A. Voors (Groningen, NL)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal PRO

Speaker: Doctor M. Packer (Dallas, US)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal CON

Speaker: Professor A. Voors (Groningen, NL)

Thumbnail

Access the full session

First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan?

Speakers: Professor G. Filippatos, Doctor M. Packer, Professor A. Voors, Doctor M. Packer, Professor A. Voors
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Related content

Open Access

Evidence-based strategies to achieve low-risk status.

27 August 2021

ESC Premium Access

Approach to the patient with pulmonary hypertension: essential knowledge.

27 August 2021

Open Access

Your treatment approach in clinical practice.

27 August 2021

ESC 365 is supported by

logo Novo Nordisk